标题
Potentiating prostate cancer immunotherapy with oncolytic viruses
作者
关键词
-
出版物
Nature Reviews Urology
Volume 15, Issue 4, Pages 235-250
出版商
Springer Nature
发表日期
2018-02-13
DOI
10.1038/nrurol.2018.10
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Functional Screening Identifies Human miRNAs that Modulate Adenovirus Propagation in Prostate Cancer Cells
- (2017) Jasmina Hodzic et al. HUMAN GENE THERAPY
- Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
- (2017) Abhishek D. Garg et al. IMMUNOLOGICAL REVIEWS
- Current status of clinical trials assessing oncolytic virus therapy for urological cancers
- (2017) Satoru Taguchi et al. INTERNATIONAL JOURNAL OF UROLOGY
- Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies
- (2017) Zoila Lopez-Bujanda et al. JOURNAL OF LEUKOCYTE BIOLOGY
- TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs
- (2017) Haejung Won et al. JOURNAL OF LEUKOCYTE BIOLOGY
- MHC-I Ligand Discovery Using Targeted Database Searches of Mass Spectrometry Data: Implications for T-Cell Immunotherapies
- (2017) J. Patrick Murphy et al. JOURNAL OF PROTEOME RESEARCH
- Oncolytic Virotherapy: A Contest between Apples and Oranges
- (2017) Stephen J. Russell et al. MOLECULAR THERAPY
- Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity
- (2017) David Olagnier et al. MOLECULAR THERAPY
- Effective combinatorial immunotherapy for castration-resistant prostate cancer
- (2017) Xin Lu et al. NATURE
- Genomic hallmarks of localized, non-indolent prostate cancer
- (2017) Michael Fraser et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy
- (2017) Ravi A. Madan et al. Nature Reviews Urology
- Targeting Th17-IL-17 Pathway in Prevention of Micro-Invasive Prostate Cancer in a Mouse Model
- (2017) Qiuyang Zhang et al. PROSTATE
- Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers
- (2017) Dylan J. Fehl et al. VIRUS RESEARCH
- The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
- (2017) Nora Ness et al. Oncotarget
- Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis
- (2017) Koran S. Harris et al. Stem Cells International
- Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
- (2017) Inna Serganova et al. Molecular Therapy-Oncolytics
- Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma
- (2017) Gustavo Schvartsman et al. Journal for ImmunoTherapy of Cancer
- Inflammation in Prostatic Hyperplasia and Carcinoma—Basic Scientific Approach
- (2017) Božo Krušlin et al. Frontiers in Oncology
- Immune Checkpoint Therapies in Prostate Cancer
- (2016) Sangeeta Goswami et al. CANCER JOURNAL
- mda-7/IL-24 Mediates Cancer Cell–Specific Death via Regulation of miR-221 and the Beclin-1 Axis
- (2016) Anjan K. Pradhan et al. CANCER RESEARCH
- Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity
- (2016) Christine Pasero et al. CANCER RESEARCH
- Hide-and-seek: the interplay between cancer stem cells and the immune system
- (2016) Mohammad Sultan et al. CARCINOGENESIS
- Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial
- (2016) Emmanuel S. Antonarakis et al. CLINICAL CANCER RESEARCH
- Emerging Immunotargets and Immunotherapies in Prostate Cancer
- (2016) Rodolfo Montironi et al. CURRENT DRUG TARGETS
- Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer
- (2016) D C Mansfield et al. GENE THERAPY
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Dendritic Cells Coordinate the Development and Homeostasis of Organ-Specific Regulatory T Cells
- (2016) Daniel S. Leventhal et al. IMMUNITY
- Prostate cancer
- (2016) Gerhardt Attard et al. LANCET
- Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus
- (2016) X. Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy
- (2016) Lorenzo Galluzzi et al. Nature Reviews Clinical Oncology
- Drug discovery in advanced prostate cancer: translating biology into therapy
- (2016) Timothy A. Yap et al. NATURE REVIEWS DRUG DISCOVERY
- Oncolytic virotherapy for urological cancers
- (2016) Zahid Delwar et al. Nature Reviews Urology
- Stromal PTEN inhibits the expansion of mammary epithelial stem cells through Jagged-1
- (2016) G M Sizemore et al. ONCOGENE
- Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse
- (2016) Yang Pu et al. Science Translational Medicine
- Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription
- (2016) Riina Kaukonen et al. Nature Communications
- Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection
- (2016) Oded Danziger et al. Oncotarget
- NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets
- (2016) Morten Nielsen et al. Genome Medicine
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
- (2016) Douglas G. McNeel et al. Journal for ImmunoTherapy of Cancer
- Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
- (2016) Hasan Rehman et al. Journal for ImmunoTherapy of Cancer
- A Perspective of Immunotherapy for Prostate Cancer
- (2016) Ida Silvestri et al. Cancers
- VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection
- (2015) Rozanne Arulanandam et al. CANCER CELL
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology
- (2015) A. Hoos et al. CLINICAL CANCER RESEARCH
- Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans
- (2015) Ali Amin Al Olama et al. HUMAN MOLECULAR GENETICS
- Strategies for combining immunotherapy with radiation for anticancer therapy
- (2015) Steven N Seyedin et al. Immunotherapy
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantifying epitope presentation using mass spectrometry
- (2015) Nathan P. Croft et al. MOLECULAR IMMUNOLOGY
- Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy
- (2015) Shabnam Shalapour et al. NATURE
- Spatial genomic heterogeneity within localized, multifocal prostate cancer
- (2015) Paul C Boutros et al. NATURE GENETICS
- Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity
- (2015) Carolina S Ilkow et al. NATURE MEDICINE
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- A basal stem cell signature identifies aggressive prostate cancer phenotypes
- (2015) Bryan A. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
- (2015) Youra Kim et al. Viruses-Basel
- Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic
- (2015) Siddik Sarkar et al. OncoImmunology
- Trial Watch—Oncolytic viruses and cancer therapy
- (2015) Jonathan Pol et al. OncoImmunology
- Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial
- (2014) B. Gurel et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Viruses for Tumor Therapy
- (2014) John Bell et al. Cell Host & Microbe
- Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer
- (2014) Y-F Yang et al. GENE THERAPY
- Prospective Randomized Phase 2 Trial of Intensity Modulated Radiation Therapy With or Without Oncolytic Adenovirus-Mediated Cytotoxic Gene Therapy in Intermediate-Risk Prostate Cancer
- (2014) Svend O. Freytag et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Sex steroid blockade enhances thymopoiesis by modulating Notch signaling
- (2014) Enrico Velardi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
- (2014) Mahesh Yadav et al. NATURE
- Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation
- (2014) Haydn T. Kissick et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
- (2014) VOLKER SCHIRRMACHER et al. Oncology Letters
- Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
- (2014) Shashi Gujar et al. OncoImmunology
- Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation
- (2014) Shashi A. Gujar et al. Frontiers in Oncology
- Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
- (2013) Matthew D. Vesely et al. Annals of the New York Academy of Sciences
- Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
- (2013) S A Gujar et al. BRITISH JOURNAL OF CANCER
- Targeting autophagy to enhance oncolytic virus-based cancer therapy
- (2013) Songshu Meng et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer
- (2013) S O Freytag et al. GENE THERAPY
- Virus infection, antiviral immunity, and autoimmunity
- (2013) Daniel R. Getts et al. IMMUNOLOGICAL REVIEWS
- Targeting and Killing of Metastatic Cells in the Transgenic Adenocarcinoma of Mouse Prostate Model With Vesicular Stomatitis Virus
- (2013) Maryam Moussavi et al. MOLECULAR THERAPY
- Suppression of Antiviral Innate Immunity by Sunitinib Enhances Oncolytic Virotherapy
- (2013) Babal K Jha et al. MOLECULAR THERAPY
- Multifaceted Therapeutic Targeting of Ovarian Peritoneal Carcinomatosis Through Virus-induced Immunomodulation
- (2013) Shashi Gujar et al. MOLECULAR THERAPY
- Cancer immunotherapy
- (2013) Lauren Gravitz NATURE
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Evaluation of ERG responsive proteome in prostate cancer
- (2013) Shyh-Han Tan et al. PROSTATE
- Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
- (2013) Jennifer L Bishop et al. Journal for ImmunoTherapy of Cancer
- Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models
- (2012) B J Passer et al. CANCER GENE THERAPY
- A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer
- (2012) M A Trujillo et al. CANCER GENE THERAPY
- Macrophage Delivery of an Oncolytic Virus Abolishes Tumor Regrowth and Metastasis after Chemotherapy or Irradiation
- (2012) M. Muthana et al. CANCER RESEARCH
- Increased CD8+ T-cell Function following Castration and Immunization Is Countered by Parallel Expansion of Regulatory T Cells
- (2012) S. Tang et al. CANCER RESEARCH
- Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
- (2012) Sonia Tusell Wennier et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Ravi A Madan et al. LANCET ONCOLOGY
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Cancer immunotherapy: a paradigm shift for prostate cancer treatment
- (2012) Dev Karan et al. Nature Reviews Urology
- Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression
- (2012) Suzanne Ostrand-Rosenberg et al. SEMINARS IN CANCER BIOLOGY
- Opposing effects of androgen ablation on immune function in prostate cancer
- (2012) Shuai Tang et al. OncoImmunology
- Targeting Tumor Vasculature With an Oncolytic Virus
- (2011) Caroline J Breitbach et al. MOLECULAR THERAPY
- Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer
- (2011) Shashi A Gujar et al. MOLECULAR THERAPY
- The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
- (2011) Kelley A Parato et al. MOLECULAR THERAPY
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors
- (2011) Timothy Kottke et al. NATURE MEDICINE
- Immunotherapy for the treatment of prostate cancer
- (2011) Giuseppe Di Lorenzo et al. Nature Reviews Clinical Oncology
- T cells localized to the androgen-deprived prostate are TH1 and TH17 biased
- (2011) Matthew D. Morse et al. PROSTATE
- Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial
- (2010) J. M. Schenk et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Oncolysis of Prostate Cancers Induced by Vesicular Stomatitis Virus in PTEN Knockout Mice
- (2010) M. Moussavi et al. CANCER RESEARCH
- Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic
- (2010) C. M. Thirukkumaran et al. CANCER RESEARCH
- Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer
- (2010) P Castelo-Branco et al. GENE THERAPY
- Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity
- (2010) S. A. Gujar et al. MOLECULAR CANCER THERAPEUTICS
- B-cell-derived lymphotoxin promotes castration-resistant prostate cancer
- (2010) Massimo Ammirante et al. NATURE
- T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics
- (2010) Yael S. Barach et al. TRENDS IN MOLECULAR MEDICINE
- Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells
- (2009) B J Passer et al. CANCER GENE THERAPY
- Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
- (2009) Ravi A Madan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Oncolytic viruses from the perspective of the immune system
- (2009) Ramon Alemany et al. Future Microbiology
- Oncolytic virus therapy for prostate cancer
- (2009) Hiroshi Fukuhara et al. INTERNATIONAL JOURNAL OF UROLOGY
- Sustained and NK/CD4+ T Cell-Dependent Efficient Prevention of Lung Metastasis Induced by Dendritic Cells Harboring Recombinant Sendai Virus
- (2009) A. Komaru et al. JOURNAL OF IMMUNOLOGY
- Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer
- (2009) Chunsheng Liu et al. PROSTATE
- Human prostate-infiltrating CD8+T lymphocytes are oligoclonal and PD-1+
- (2009) Karen S. Sfanos et al. PROSTATE
- Adenoviral-Mediated Endothelial Precursor Cell Delivery of Soluble CD115 Suppresses Human Prostate Cancer Xenograft Growth in Mice
- (2009) Trevor Lucas et al. STEM CELLS
- An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors
- (2008) N Lei et al. CANCER GENE THERAPY
- A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
- (2008) L. Vidal et al. CLINICAL CANCER RESEARCH
- Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing
- (2008) K. S. Sfanos et al. CLINICAL CANCER RESEARCH
- A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients
- (2008) J-L Li et al. GENE THERAPY
- Toll-like receptor–mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway
- (2008) Weiping Cao et al. NATURE IMMUNOLOGY
- Advances in Specific Immunotherapy for Prostate Cancer
- (2007) Andrea Kiessling et al. EUROPEAN UROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More